Earnings Preview: MYGN to Report Financial Results Post-market on May 06
Myriad Genetics Announces Survey Results on Depression, Anxiety
Concerns About Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed With Depression and Anxiety, According to the GeneSight Mental Health Monitor
Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025
Express News | Myriad Genetics To Present At AACR Annual Meeting On Apr. 28
Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting
Insiders At Myriad Genetics Sold US$6.5m In Stock, Alluding To Potential Weakness
Leerink Partners Maintains Myriad Genetics(MYGN.US) With Hold Rating
Myriad Genetics Releases Study Results That Shows Patients With Depression Had Fewer Psychiatric Hospitalizations After GeneSight Testing
Express News | Myriad Genetics Announces Study Results Show Patients With Depression Had Fewer Psychiatric Hospitalizations After Genesight Testing
Myriad Genetics Price Target Cut to $14.00/Share From $18.00 by Goldman Sachs
Goldman Sachs Maintains Myriad Genetics(MYGN.US) With Buy Rating, Cuts Target Price to $14
TD Cowen Maintains Myriad Genetics(MYGN.US) With Hold Rating, Cuts Target Price to $11
Myriad Genetics Cut to Neutral From Buy by Guggenheim
Guggenheim Downgrades Myriad Genetics(MYGN.US) to Hold Rating
Press Release: Myriad Genetics Announces Inducement Awards
Press Release: Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer
Express News | Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer
Scotiabank Maintains Myriad Genetics(MYGN.US) With Buy Rating, Cuts Target Price to $20
Scotiabank Maintains Sector Outperform on Myriad Genetics, Lowers Price Target to $20